BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
This widow influencer is using jokes to cope after her husband's death. It's OK if people don't get it. - 2Novo Nordisk cuts Wegovy price in South Africa for a second time
- 3Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
- 4Extremely Rare Snub-Nosed Monkey Was Just Born for the First Time Outside of Asia
- 5What's A Decent FICO rating?
- A definitive Manual for Choosing Indoor Plants Ideal for Your Space
- The Most Astonishing Arising Advances to Watch
- Manual for 6 Busssiness Class Flights
- What is Fusarium graminearum, the fungus a Chinese scientist pleaded guilty to smuggling into the US?
- Starbucks' new 'Bearista' cup is causing a stir — and is being listed on eBay for $600
- Where is Santa right now? NORAD tracks his 2025 Christmas Eve flight.
- Explainer-Why are hepatitis B vaccines given to newborns?
- Greece eyes migrant repatriation centres outside the EU
- What is the Insurrection Act? Can Trump really use the military to 'put an end' to Minneapolis ICE protests?
